AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04493320
Drug: Carbidopa/levodopa
RxNorm normalized name: CARBIDOPA/LEVODOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-450mg carbidopa/levodopa 3 times daily
Trial: NCT04493320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa-matched placebo tablet 3 times daily
Trial: NCT05670782
Drug: KM-819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral doses of KM-819 once-daily
Trial: NCT05670782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo once-daily
Trial: NCT05990153
Drug: clinical practice drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug treatment according to the medical indications of clinical practice
Trial: NCT05578196
Drug: fecal bacteria solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
Trial: NCT05578196
Drug: physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline solution 20ml
Trial: NCT05243953
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
Trial: NCT05243953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Trial: NCT04601610
Drug: KN046 （PD-L1/CTLA4 BsAb）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN046 5mg/kg Q3W
Trial: NCT04969510
Drug: 10 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT04969510
Drug: 20 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT04969510
Drug: 40 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT04969510
Drug: 60 mg PRAX-114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT04969510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment
Trial: NCT00000717
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04617054
Drug: AB-106
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg QD for each subjects.
Trial: NCT04853992
Drug: LEO 152020
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
Trial: NCT04853992
Drug: LEO 152020 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
Trial: NCT04859621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
Trial: NCT05256134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as per the dosing schedule described in the Arm description.
Trial: NCT06348706
Drug: Dipeptidyl peptidase 4 (DPP-4) inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
Trial: NCT05477498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
Trial: NCT03698448
Drug: OligoG Dry powder for inhalation
RxNorm normalized name: capryl oligoglucoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 capsules Dry Powder for Inhalation, BID
Trial: NCT05199519
Drug: IBI345
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI345 CAR-T cell injection by intravenous infusion
Trial: NCT06193889
Drug: Standard lymphodepletion regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lymphodepletion regimen
Trial: NCT05934955
Drug: Placebo matching BI 1839100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1839100
Trial: NCT06611007
Drug: embolization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
Trial: NCT05472662
Drug: Placebo 152a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
Trial: NCT05472662
Drug: Placebo 134a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
Trial: NCT06297954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo 10 ml IV in a single dose prior to randomization.
Trial: NCT04919863
Drug: NTP42:KVA4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
Trial: NCT04919863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
Trial: NCT04860063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
Trial: NCT05352347
Drug: NuSepin® 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuSepin® 0.2 mg/kg in 100mL NS bid
Trial: NCT05352347
Drug: NuSepin® 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuSepin® 0.4 mg/kg in 100mL NS bid
Trial: NCT05352347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) 100mL bid
Trial: NCT05145179
Drug: SSGJ-705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
Trial: NCT06385561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally twice daily.
Trial: NCT05250648
Drug: complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
Trial: NCT00081536
Drug: Aroplatin (Liposomal NDDP) in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05531097
Drug: HSK31679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple oral doses of HSK31679
Trial: NCT05531097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06746311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, containing no active ingredient, administered subcutaneouly
Trial: NCT05967052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06504420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
Trial: NCT04938323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .1 mL of diluent (saline) given intradermally at baseline
Trial: NCT06086613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection.
Trial: NCT06613009
Drug: IBI3009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
Trial: NCT06213935
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
Trial: NCT04051801
Drug: Dose Escalation of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose levels of the cohorts will be increased step wise
Trial: NCT04830020
Drug: HMW-HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerolized administration b.i.d.
Trial: NCT06128070
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04729309
Drug: [12C] RO7049389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral \[12C\] RO7049389.
Trial: NCT04729309
Drug: [13C] RO7049389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV \[13C\] RO7049389.
Trial: NCT04729309
Drug: [14C] RO7049389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an oral suspension of \[14C\] RO7049389.
Trial: NCT05321511
Drug: Ovitrelle® (hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
Trial: NCT05321511
Drug: Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
Trial: NCT04849065
Drug: Placebo / Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
Trial: NCT03184155
Drug: Sterile Saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
Trial: NCT05607641
Drug: Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Trial: NCT05496335
Drug: AGN-151586
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT05496335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT00000723
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000723
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05297695
Drug: Triple therapy for H. pylori infection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
Trial: NCT05980195
Drug: Standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months
Trial: NCT03415061
Drug: Regular Insulin, Human 100 UNT/ML
RxNorm normalized name: regular insulin, human 100 UNT/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
Trial: NCT03415061
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Trial: NCT05217719
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
Trial: NCT04706286
Drug: CKD-501, D759, D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
Trial: NCT04706286
Drug: CKD-393 0.5/100/1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
Trial: NCT04715932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Trial: NCT05033093
Drug: Root Canal Sealants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
Trial: NCT05219084
Drug: intra-articular hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml; of normal; saline were injected inside the hip joint
Trial: NCT05607641
Drug: Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Trial: NCT05219084
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hip denervation and intra-articular hydration were conducted together
Trial: NCT05219084
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal; saline was injected subcutaneously
Trial: NCT00006199
Drug: R115777 (farnesyl transferase inhibitor)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04060316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given as a nasal spray using an atomizer
Trial: NCT05607641
Drug: Neospastil, solution for injection then Neospastil, film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Trial: NCT06399809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be matched to the Fisetin intervention
Trial: NCT05009680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally twice a day
Trial: NCT05608980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily eyelid wipes for 2 weeks
Trial: NCT04720131
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
Trial: NCT03877991
Drug: CBD-LNL capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
Trial: NCT03877991
Drug: CBD powder form capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
Trial: NCT04602715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control
Trial: NCT05943821
Drug: Optional intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up.
Trial: NCT05868577
Drug: Corticosteroid injection (CSI) with local anesthetic (LA)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PI will then administer the injection using an infracalcaneal needle peppering
Trial: NCT06632561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pills one tablet daily for 6 months
Trial: NCT05868577
Drug: Local anesthetic (LA) with Saline injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PI will then administer the injection using an infracalcaneal needle peppering
Trial: NCT05873712
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04360096
Drug: ZYESAMI™ (aviptadil acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
Trial: NCT04360096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Inhalation
Trial: NCT00063219
Drug: MAC-321
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04913805
Drug: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
Trial: NCT04681066
Drug: CM-4620 Injectable Emulsion or CM-4620-IE
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
Trial: NCT05644600
Drug: AZD5055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
Trial: NCT06633471
Drug: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
Trial: NCT04959591
Drug: intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental(pre): administration of IV acetaminophen